Skip to search formSkip to main contentSkip to account menu

PD 166326

Known as: PD166326 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

PyridinesPyrimidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
the mutation pattern for PD166326, an alternative Abl kinase inhibitor A cell-based screen for resistance of Bcr-Abl positive leukemia identifies
Abstract In Ph+ leukemia, point mutations within the Bcr-Abl kinase domain emerged as a major mechanism of resistance toward… 
Review
2006
Review
2006
New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
Imatinib mesylate, Abl tyrosine kinase inhibitor, has improved the treatment of Bcr-Abl-positive leukemia such as chronic myeloid… 
2006
2006
Comparison of the cytotoxic effects of receptor tyrosine kinase inhibitors on macrophage functions; possible side effects in the immune defense.
2005
2005
Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by Leguay et al
Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients… 
2004
2004
S-phase Inhibition of Cell Cycle Progression by a Novel Class of Pyridopyrimidine Tyrosine Kinase Inhibitors
Increased activity of the src family of oncogenic tyrosine kinases is seen in many human tumors and pharmacologic inhibitors of… 
Review
2003
Review
2003
Advances in Brief A Novel Pyridopyrimidine Inhibitor of Abl Kinase Is a Picomolar Inhibitor of Bcr-abl-driven K 562 Cells and Is Effective against STI 571-resistant Bcr-abl Mutants 1
Inhibition of the constitutively active Bcr-abl tyrosine kinase (TK) by STI571 has proven to be a highly effective treatment for… 
2003
2003
Is another bcr-abl inhibitor needed for chronic myelogenous leukemia?
The recent success of STI-571 (Imatinib mesylate; Gleevec) in the chronic phase of CML[2][1] is a milestone in the history of… 
2002
2002
c-Kit Receptor Tyrosine Kinases Characterization of Potent Inhibitors of the Bcr-Abl and the Updated
The early stage of chronic myelogenous leukemia (CML) is caused by the tyrosine kinase Bcr-Abl. Imatinib mesylate (also known as… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)